Daniel Blom

Daniel Blom currently serves as Chief Scientific Officer and Chief Technology Officer at Ampersand Biomedicines since January 2022. Prior to this role, Daniel held the position of Senior Vice President Drug Discovery and Development and Vice President Biologics Drug Development at Cygnal Therapeutics from July 2019 to November 2021. Daniel's experience at GSK spanned from November 2013 to June 2019 as Director of Biology for both Discovery Partnerships with Academia and Virtual Proof of Concept. At Merck & Co, Inc, Daniel worked from November 2004 to October 2013 as Director of Biologics Strategy focusing on Cardiovascular Diseases. Earlier in the academic field, Daniel was a postdoctoral fellow at both Harvard Medical School from 2001 to 2004 and the University of Amsterdam from 1999 to 2001. Daniel earned a PhD in Biochemistry and an MSc in Chemistry, both from the University of Amsterdam, completing the PhD in 1999 after obtaining the MSc in 1993.